Epidermal growth factor receptor double mutations in non-small cell cancer patients
作者单位：Department of Medical OncologyZhejiang Cancer Hospital
会议名称：《浙江省免疫学会第十次学术大会》
会议日期：2016年
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
摘 要：Background:Epidermal growth factor receptor(EGFR) mutations occur in 70%of patients with non-small-cell cancer(NSCLC).These mutations are concentrated in exons 18-21,common mutations enhances clinical sensitivity to tyrosine kinase inhibitors(TKIs).However,the relation between EGFR double activating mutations with the therapeutic efficacy of EGFR-TKIs is still not well ***:In our study,we detected EGFR mutations in NSCLC with pyrosequencing asssy and mutant-enriched PCR,and further analyzed the correlation between EGFR mutation type and clinicopathologic features of ***:In this study,7 patients with double EGFR mutation,including L858 R +DelE746-A750,L858 R+S768 I,L858 R+T790 M.85.7%were *** median age was 62 years old.L858 R + DelE746-A750 double mutations had a higher sensitivity to TKI and a substantially longer overall survival than the other two single-activating *** L858 R+T790 M mutations confer EGFR-TKI resistance in NSCLC ***:These data might inform therapeutic options for patients with non-small-cell lung cancer harbouring EGFR double *** propose that positive EGFR double-activating somatic mutation may be a good prognostic factor.